Tackling Tuberculosis in Latvia

نویسنده

  • Melanie Zipperer
چکیده

0380 With a forceful gesture, the delicate blond unlocks the heavy door of a cell in Riga’s Central Prison clinic (Figure 1). Her name is Dr. Inga Nagele. She is the head of the clinic’s tuberculosis (TB) unit. She opens the door to check on three female prisoners who have just been admitted. The conditions in the cell are bleak. Washing hangs on a line that stretches from one wall to the other. The bars on the small window hardly let any light into the room, and a bucket in the corner serves as a toilet. All the women were infected with TB at the prison. “Living conditions in Latvia’s prisons are miserable. This is ideal for a relentless spread of the life-threatening lung bacteria and other communicable diseases”, says Dr. Nagele. Because of permanent overcrowding, poor hygiene, and frequent relocation of prisoners within Latvia’s 15 prisons, two-thirds of inmates infected with TB developed the disease once they were locked up, she says. Latvia has 352 prisoners per 100 000 individuals in the population [1]. This number makes it one of the countries with the highest proportion of prisoners in the European Union, according to Mihails Azarenko, Chief of Riga’s Central Prison. It is particularly high when compared with Denmark, for example, which has only 64 prisoners per 100 000 individuals [1].

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Multidrug-resistant Tuberculosis Detection, Latvia

To improve multidrug-resistant tuberculosis (MDR-TB) detection, we successfully introduced the rpoB gene mutation line probe assay into the national laboratory in Latvia, a country with epidemic MDR-TB. The assay detected rifampin resistance with 91% sensitivity and 96% specificity within 1 to 5 days (vs. 12-47 days for BACTEC).

متن کامل

Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.

Latvia is a high-priority country in the fight against tuberculosis (TB) in Europe, with an estimated TB incidence of 41 per 100000 in 2015 [1]. In spite of an improving TB control programme [2] and cure rates reaching 80% for new and retreatment TB cases notified in 2014, multidrug-resistant (MDR-) TB (defined as TB resistant to rifampicin and isoniazid) rates in Latvia remain high [1]. An est...

متن کامل

Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia

Few studies have examined whether the Xpert MTB/RIF test improves time to treatment initiation for persons with multidrug-resistant tuberculosis (MDR TB). We determined the impact of this test in Latvia, where it was introduced in 2010. After descriptive analyses of pulmonary MDR TB patients in Latvia during 2009-2012, time to treatment initiation was calculated, and univariate and multivariabl...

متن کامل

Multi- and extensively drug-resistant tuberculosis in Latvia: trends, characteristics and treatment outcomes.

SETTING Drug-resistant tuberculosis (TB) is an important public health problem in Latvia. OBJECTIVE To document trends, characteristics and treatment outcomes of registered patients with multi-drug-resistant (MDR-) and extensively drug-resistant (XDR-) TB in Latvia from 2000 to 2010. DESIGN A retrospective national cohort study. RESULTS Of 1779 patients, 1646 (92%) had MDR- and 133 (8%) X...

متن کامل

Pediatric and adolescent tuberculosis in Latvia, 2011-2014: case detection, diagnosis and treatment.

OBJECTIVE To perform a comprehensive analysis of case detection, diagnosis and treatment of tuberculosis (TB) in children and adolescents in Latvia, and to evaluate the utility of the current approach. DESIGN A retrospective study of all Latvian children and adolescents diagnosed with TB from 1 January 2011 to 31 December 2014. RESULTS Of 3081 patients diagnosed with TB during 2011-2014, 25...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • PLoS Medicine

دوره 2  شماره 

صفحات  -

تاریخ انتشار 2005